Growth hormone data
Response to a request for information on the use of somatropin (growth hormone).
26 September 2019
[name and contact details redacted]
Dear [name redacted]
REQUEST FOR INFORMATION – GROWTH HORMONE
Thank you for your request dated 30 August under the Official Information Act 1982 (OIA) for information relating to growth hormone (somatropin). You asked for:
Data on the number of new patients getting growth hormone each year (for the last 10 years) by age (under 18 patient group), sex and ethnicity, if possible by indication with a special interest in those with GH deficiency.
The information requested is provided on the following pages.
PHARMAC approaches its assessment of requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you, it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).
We trust that this information answers your query. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Yours sincerely
Alison Hill
Director, Engagement and Implementation
Table 1: Number of people under at the time of dispensing, dispensed somatropin in the community between June 2010 and June 2018, split by ethnicity and gender.
Gender |
Ethnicity |
2009/10 |
2010/11 |
2011/12 |
2012/13 |
2013/14 |
2014/15 |
2015/16 |
2016/17 |
2017/18 |
Female |
Asian |
12 |
15 |
14 |
14 |
15 |
16 |
22 |
24 |
26 |
Female |
European |
88 |
86 |
89 |
90 |
87 |
103 |
97 |
96 |
105 |
Female |
Maori |
16 |
17 |
22 |
26 |
26 |
32 |
32 |
29 |
36 |
Female |
MELAA |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Female |
Other |
<10 |
||||||||
Female |
Pacific Island |
<10 |
12 |
<10 |
<10 |
11 |
<10 |
<10 |
10 |
<10 |
Female |
Unspecified |
<10 |
<10 |
<10 |
<10 |
|||||
Male |
Asian |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
10 |
11 |
11 |
Male |
European |
64 |
64 |
72 |
88 |
89 |
87 |
85 |
96 |
98 |
Male |
Maori |
27 |
25 |
28 |
31 |
29 |
35 |
33 |
30 |
39 |
Male |
MELAA |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Male |
Other |
<10 |
<10 |
<10 |
||||||
Male |
Pacific Island |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Male |
Unspecified |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
||
Total |
240 |
244 |
256 |
281 |
275 |
296 |
296 |
307 |
336 |
Note: This data for ethnicity is prioritised ethnicity. The prioritised ethnicity data assigns each person a primary ethnicity, with the primary ethnicity selected in a specific order, called the Ethnic Group priority. For example, if a person identifies as Māori for one of their 3 ethnicities then their primary ethnicity will be noted as Māori, as the Māori ethnicity is ranked first in the Ethnic Group priority list.
Table 2: Number of people under 18, dispensed somatropin in the community between June 2010 and June 2018, with indication under which approval was granted.
Indication |
2009/10 |
2010/11 |
2011/12 |
2012/13 |
2013/14 |
2014/15 |
2015/16 |
2016/17 |
2017/18 |
Exceptional Circumstances |
<10 |
<10 |
<10 |
<10 |
|||||
Growth hormone deficiency in children |
130 |
140 |
146 |
156 |
|||||
Panel Approvals |
234 |
238 |
253 |
275 |
272 |
218 |
|||
Short stature due to chronic renal insufficiency |
10 |
10 |
<10 |
<10 |
|||||
Short stature without growth hormone deficiency |
87 |
98 |
109 |
114 |
|||||
Specific Pre-Approval |
<10 |
12 |
12 |
13 |
|||||
Turner syndrome |
52 |
48 |
40 |
46 |
|||||
Prader-Willi syndrome |
32 |
31 |
35 |
34 |
Note - There is double counting in this table as some people were approved under more than one indication in the same year.
<10